ATI Medical Appoints Dr. Stuart Holden to Its Scientific Advisory Board.Business Editors & Health/Medical Writers BIOWIRE2K SAN DIEGO--(BW HealthWire)--May 21, 2002 ATI (ATI Technologies Inc., Markham Ontario, http://ati.amd.com) A leading manufacturer of graphics chips and display adapters. Founded in 1985 by K. Y. Ho, Benny Lau and Lee Lau, ATI chips and boards are widely used by OEMs. Medical Inc., developer of a new approach to brachytherapy treatments for localized cancer, today announced the appointment of Dr. Stuart Holden to its Scientific Advisory Board. Dr. Holden has been a partner in Tower Urology urology Medical specialty dealing with the urinary system and male reproductive organs. It traces its origin to medieval lithologists, itinerant healers who specialized in surgical removal of bladder stones. and an attending surgeon at Cedars-Sinai Medical Center Cedars-Sinai Medical Center is a world-renowned hospital located in Los Angeles, California. History Cedars-Sinai is the result of a merger in 1961 between two major Los Angeles hospitals, Cedars of Lebanon and Mount Sinai Home for the Incurables, with Steve Broidy as since 1978. Since 2000, he has been the Warschaw, Roberson, Law Chair holder and Director of the Cedars-Sinai Prostate Cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. Center. For the past nine years, Dr. Holden has been the Medical Director of CaP CURE, a public charity that is the world's largest non-governmental funder of prostate cancer research. Dr. Holden has served on the Prostate Advisory Board of the American Cancer Society American Cancer Society, n.pr established in 1913, this national volunteer-based health organization is committed to the elimination of cancer through prevention and treatment and to diminishing cancer suffering through advocacy, scholarship, research, , the integration panel of the Department of Defense Prostate Cancer Research Project and is the Chairman of the Scientific Advisory Board of ProQuest Investments, a private investment fund that focuses on advancing leading anti-cancer technologies. He is also on the Board of Directors of ACMI Corp. and Acurian, a private company that accelerates patient accruals in clinical trails. Dr. Holden received his B.S. from the University of Wisconsin and his M.D. from Cornell University Medical College. He has been a Diplomat of the American Board of Urology since 1977. "We are delighted to have Dr. Holden on our Scientific Advisory Board," said W. Tate Scott, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of ATI Medical. "Dr. Holden has spent over 25 years treating patients for prostate cancer, and he is dedicated to bringing new technologies to market to improve patient care. This is ATI's mission as well, making Dr. Holden an excellent addition to our Board." "I look forward to working with ATI Medical," said Dr. Stuart Holden. "I've been interested in their thermal therapy technology for several years, and am pleased that the Company is adding radiation to their armamentarium ar·ma·men·tar·i·um n. pl. ar·ma·men·tar·i·ums or ar·ma·men·tar·i·a The complete equipment of a physician or medical institution, including drugs, books, supplies, and instruments. . One of the Company's first products will be a thermal brachytherapy implant. This implant is intended to deliver a standard therapeutic dose of radiation, and then to be heated to thermally ablate ab·late v. To remove or destroy the function of. ablate to remove, especially by cutting. ablate verb To remove; excise tissue, if the cancer recurs locally. It is estimated that 20-30 percent of prostate cancer patients treated with brachytherapy have their cancer recur within 5 years, and there are few secondary, curative options for these patients. The potential to thermally ablate the prostatic tissue in these patients may prove to be another option. Building two therapies into one implant is an ingenious idea." Prostate Cancer is the second leading cause of cancer death in men. The American Cancer Society estimates that 189,000 new cases will be diagnosed in the U.S. in 2002, and over 30,000 men will die of the disease. ATI Medical is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. that is focused on the development and commercialization of a family of implants for the treatment of prostate cancer and other diseases. These products, which are still under development, are intended to apply heat and/or radiation simultaneously or separately to treat solid tumors. Visit ATI Medical on the Web at atimedical.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion